With 2026 already off to a hot start, and the TSX continuing to touch new all-time highs, it’s getting harder to find high-quality Canadian stocks that can rally rapidly throughout the year.
While the entire market has momentum right now, many high-quality Canadian stocks are already near or above their fair value.
So, if you’re looking to add Canadian stocks today with significant growth potential in 2026, you don’t just have to try to find high-quality companies; you need to find high-quality stocks that have significant potential trade well below their fair value.
The good news for investors, though, is that while there aren’t many high-quality Canadian stocks trading cheaply, one stock that continues to have significant potential, WELL Health Technologies (TSX: WELL) is trading significantly below its fair value.
Source: Getty Images
Why is WELL Health one of the best Canadian stocks to buy now?
There are several reasons to consider an investment in WELL Health today. First off, WELL is one of Canada’s leading omnichannel digital health companies. And while it initially grew in popularity during the pandemic for its digital health apps and telehealth businesses, today, it also operates the country’s largest network of outpatient clinics.
The company continues to demonstrate its ability to grow rapidly through acquisitions. In fact, WELL added 41 clinics in 2025 alone, reaching 252 nationwide, which was a 19% increase.
At the same time that it continues to focus on growing its patient services segment, though, WELL continues to provide tech solutions like electronic medical records, telemedicine, and AI-powered tools for physicians, which is why it’s one of the best growth stocks to buy in the highly defensive healthcare sector.
WELL’s impressive growth is hard to ignore
What’s most impressive about WELL is that it continues to translate its acquisitions into growth of both its revenue and profitability. And the more businesses and clinics WELL acquires, the better it can scale its costs.
For example, its third-quarter revenues in 2025 jumped 56% year over year to $365 million. Furthermore, its patient visits hit 4.3 million in 2025, a 37% increase for the full year.
In addition to the rapid increase in revenue, though, WELL is also improving its profitability. For example, its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) have reached record levels in recent quarters, with margins continuing to improve.
In addition to the compelling growth in its revenue and profitability, though, WELL also has more catalysts for a stock rally this year as it continues to look to sell off some of its non-core digital health assets and spin out WELLSTAR, its popular Software as a Service business.
Those non-core asset sales in the U.S. should bring in significant cash at attractive multiples that WELL can use to reinvest in higher-growth Canadian operations. And the planned spin-out of WELLSTAR in mid-2026 is expected by many analysts to unlock billions in value for shareholders, giving the stock a major re-rating catalyst.
So, it’s no surprise that all seven analysts covering WELL right now are giving it a buy rating. Furthermore, its average analyst target price of $7.29 is more than 85% higher than WELL’s share price at the time of writing.
So, if you’re looking for a high-quality Canadian stock that can rally rapidly through 2026 and beyond, there’s no question that WELL Health is a top pick.
